GWPH GW Pharmaceuticals Plc

103.52
-2.39  -2%
Previous Close 105.91
Open 106.75
Price To Book 4.45
Market Cap 3,200,132,083
Shares 30,913,177
Volume 843,405
Short Ratio
Av. Daily Volume 821,363
Stock charts supplied by TradingView

NewsSee all news

  1. GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting

    LONDON and CARLSBAD, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with

  2. GW Pharmaceuticals to Present at Upcoming Investor Conferences

    CARLSBAD, Calif., Nov. 22, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ:GWPH, GW, the Company or the Group)), the world leader in the science, development,

  3. GW Pharmaceuticals receives positive NICE recommendation for EPIDYOLEX® (cannabidiol) oral solution for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy

    GW also welcomes the positive guideline recommendation for Sativex® (nabiximols) for the treatment of spasticity due to multiple sclerosis as part of NICE's evaluation of cannabis-based medicinal products (CBMPs)

  4. GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Third Quarter Ended September 30, 2019

    - Epidiolex U.S. year to date net sales of $188.0 million, including Q3 net sales of $86.1 million - - Conference call today at 4:30 p.m. ET - CARLSBAD, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc

  5. GW Pharmaceuticals to Present at Upcoming Investor Conferences

    CARLSBAD, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ:GWPH, GW, the Company or the Group)), the world leader in the science, development,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data released February 7, 2017.
Tetrahydrocannabinol (THC) and cannabidiol (CBD)
Glioblastoma Multiform- cancer
Phase 2 open-label trial to commence 1Q 2019.
GWP42006 (CBDV)
Rett syndrome
Phase 3 initiated December 2016. Part A nearing completion, unlikely to continue through to Part B.
Epidiolex
Infantile spasms (IS)
Phase 2 trial did not meet endpoint
GWP42004
Type 2 diabetes
Phase 3 trials failed. Evaluating whether there are any next steps
Sativex
Cancer pain
Phase 2 data released February 21, 2018 - primary endpoint not met.
GWP42006 (CBDV)
Epilepsy
Phase 2b trial to commence 1H 2020.
GWP42003
Schizophrenia
Approval announced June 25, 2018.
Epidiolex
Dravet Syndrome and Lennox-Gastaut syndrome
Phase 3 data to be presented at American Epilepsy Society meeting December 6-10, 2019. sNDA filing due early 2020.
Epidiolex
Tuberous Sclerosis Complex
Phase 3 trial planned for 4Q 2019.
Sativex
Spasticity due multiple sclerosis
GWP42006 (CBDV)
Autism
Phase 3 trial has commenced - May 6, 2019.
Epidiolex
Rett syndrome
Phase 3 data to be presented at AAN May 7, 2019.
Epidiolex GWPCARE2
Dravet Syndrome

Latest News

  1. GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting

    LONDON and CARLSBAD, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with

  2. GW Pharmaceuticals to Present at Upcoming Investor Conferences

    CARLSBAD, Calif., Nov. 22, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ:GWPH, GW, the Company or the Group)), the world leader in the science, development,

  3. GW Pharmaceuticals receives positive NICE recommendation for EPIDYOLEX® (cannabidiol) oral solution for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy

    GW also welcomes the positive guideline recommendation for Sativex® (nabiximols) for the treatment of spasticity due to multiple sclerosis as part of NICE's evaluation of cannabis-based medicinal products (CBMPs)

  4. GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Third Quarter Ended September 30, 2019

    - Epidiolex U.S. year to date net sales of $188.0 million, including Q3 net sales of $86.1 million - - Conference call today at 4:30 p.m. ET - CARLSBAD, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc

  5. GW Pharmaceuticals to Present at Upcoming Investor Conferences

    CARLSBAD, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ:GWPH, GW, the Company or the Group)), the world leader in the science, development,

  6. GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Third Quarter Ending September 30, 2019 and Host Conference Call on November 5, 2019

    CARLSBAD, Calif., Oct. 09, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH, "GW" or "the Company")), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics

  7. Microbiotica Appoints Thomas Lynch as Independent Non-Executive Chairman

    Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announces the appointment of Thomas Lynch as the new non-Executive Chairman of its Board, from 1 September 2019.

  8. GW Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2nd, 2019

    CARLSBAD, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ:GWPH, GW, the Company or the Group)), the world leader in the development and

  9. Why the Magic Mushroom Story Could be as Big as the Cannabis Boom

    PALM BEACH, Florida, Sept. 24, 2019 /PRNewswire/ -- As cannabis legalization spreads, another drug may soon follow in its footsteps -- psilocybin mushrooms.  In fact, analysts argue mushrooms may hold untapped medical

  10. GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy

    Cannabidiol oral solution is the first plant-derived cannabis-based medicine to be approved by the European Medicines Agency (EMA) Cannabidiol oral solution contains highly purified, plant-derived cannabidiol (CBD), a

  11. The Most Impressive Cannabis Statistics That Should not be Overlooked

    PALM BEACH, Florida, Sept. 5, 2019 /PRNewswire/ -- Cannabis has become the biggest story of the decade. Not only did Canada approve its use in 2018, the U.S. government has become aggressive in its attempt to legalize

  12. GW Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on Wednesday, September 11th, 2019

    CARLSBAD, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ:GWPH, GW, the Company or the Group)), the world leader in the science, development,